Hepatocellular carcinoma (HCC) ranks number three among the most frequent causes of death from solid tumors worldwide.
With obesity and fatty liver diseases as risk factors on the rise, HCC represents an ever increasing challenge.
Dr Alexander Gerbes and colleagues target therapeutic advances and most burning issues.
|There is still no curative treatment, numerous novel drugs have been proposed|
While there is still no curative treatment for most patients numerous novel drugs have been proposed, but most ultimately failed in phase III trials.
Expert key point summaries and urgent research agenda are provided regarding risk factors, including microbiota, need for prognostic and predictive biomarkers and the equivocal role of liver biopsy.
The research team highlighted therapeutic topics such as locoregional techniques, combination therapies and the potential of immunotherapy.
Dr Gerbes' team concludes, "Finally the manuscript provides a critical evaluation of novel targets and strategies for personalized treatment of HCC."